Angiodynamics INC 8-K filings

AngioDynamics announced record fiscal year 2026 results, driven by strong double-digit growth in its Med Tech segment, achieving full-year profitability and ending the year with a debt-free balance sheet.

AngioDynamics has initiated patent infringement litigation against Endovascular Engineering, Inc. regarding its thrombectomy technology.

AngioDynamics, Inc. announced the planned retirement of CEO James C. Clemmer by November 2026 and approved retention agreements for its executive leadership team to ensure a smooth transition.

AngioDynamics, Inc. presented an updated financial outlook and showcased its MedTech portfolio's strong performance and innovation at the J.P. Morgan 44th Annual Healthcare Conference.

AngioDynamics announced robust fiscal Q2 2026 results driven by double-digit Med Tech growth, increased profitability, and raised full-year guidance.

AngioDynamics, Inc. announced the successful election of Class I directors, ratification of its independent auditor, and advisory approval of executive compensation at its Annual Meeting of Shareholders on November 10, 2025.

AngioDynamics reports strong fiscal Q1 2026 results driven by 26.1% Med Tech growth, raising full-year guidance across key metrics.

AngioDynamics, Inc. announced robust financial results for its fiscal fourth quarter and full year ended May 31, 2025, showcasing accelerated profitable growth, particularly within its MedTech franchise, and significant strategic advancements.

AngioDynamics, Inc. has entered into a new $25 million secured revolving credit facility with JPMorgan Chase Bank, N.A., aimed at providing incremental financial flexibility for working capital and strategic growth initiatives.

AngioDynamics highlights its strategic focus on cardiovascular and cancer care, emphasizing innovative technologies and improved patient outcomes at its Cardiovascular Investor Event.

AngioDynamics announces positive Q3 2025 financial results with significant growth in MedTech sales and increased full-year guidance across key metrics.

AngioDynamics presented at the J.P. Morgan 43rd Annual Healthcare Conference, highlighting its strategic focus on high-growth Med Tech segments and its path to profitability.

AngioDynamics hosted a virtual investor event showcasing the NanoKnife Irreversible Electroporation (IRE) technology for prostate cancer treatment.

AngioDynamics announced positive second quarter fiscal year 2025 results, highlighted by a 25% increase in Med Tech sales and raised full year profitability guidance.

AngioDynamics held its annual shareholder meeting on November 12, 2024, where shareholders voted on key proposals including the election of directors and approval of an amended equity incentive plan.

AngioDynamics reported a 1.1% increase in pro forma net sales for the first quarter of fiscal year 2025, driven by strong growth in its Med Tech segment, while experiencing a decline in the Med Device segment.

AngioDynamics announced its fiscal year 2024 results, showcasing growth in Med Tech sales and progress in its strategic transformation.

AngioDynamics has released pro forma financial statements reflecting the impact of recent divestitures and product discontinuations, providing a clearer picture of the company's ongoing operations.

AngioDynamics announced its third quarter fiscal year 2024 results, highlighting revenue growth in its Med Tech and Med Device segments and updating its full-year guidance to reflect recent divestitures.

AngioDynamics and Becton, Dickinson and Company have reached a settlement agreement to resolve ongoing patent litigation, involving a one-time payment and future royalties.

AngioDynamics has appointed new chairs to its Audit and Nominating, Compliance and Corporate Governance Committees and reclassified a director to balance board classes following a recent retirement.

AngioDynamics announces the retirement of long-serving board member Dennis Meteny, effective January 31, 2024, leading to a reduction in the board size.

AngioDynamics presented its strategic focus on high-growth medical technology markets and provided updates on key product developments at the J.P. Morgan Healthcare Conference.